Stay updated on Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.

Latest updates to the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe study record now shows recruitment is closed to new participants, and new recruitment sites (e.g., Hunan Cancer hospital 1 and University College Hospital) along with updated navigation items were added to aid readers in understanding how to join and read the study.SummaryDifference0.3%

- Check21 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5, indicating a new version of the study documentation has been issued for the record.SummaryDifference0.0%

- Check35 days agoChange DetectedA new revision entry was added: Revision: v3.5.4, replacing the prior v3.5.3. This indicates a routine update to the Study Details page.SummaryDifference0.0%

- Check42 days agoChange DetectedThe update history now includes May 2026 entries (2026-05-08, 2026-05-07, 2026-05), while April 2026 entries (2026-04-22, 2026-04-09, 2026-04) were removed. These entries document when the page was updated, not changes to the study content.SummaryDifference0.1%

- Check57 days agoChange DetectedTwo new Chinese study sites were added: Hunan Cancer Hospital Chest Tumor Internal Medicine dept. II in Changsha and Beijing Cancer Hospital Chest Tumor Internal Medicine dept. II in Beijing, bringing total locations to 249 and updating the record to revision v3.5.3.SummaryDifference0.2%

- Check64 days agoChange DetectedThe page footer revision was updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

Stay in the know with updates to Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.